Menlo Park, California -- STATegics, Inc. announced today that the Friedreich’s Ataxia Research Alliance (FARA) has awarded the Company a new grant of $158,959 to advance its proprietary erythropoietin receptor agonist compounds for the treatment of Friedreich’s ataxia (FRDA), a rare inherited neurodegenerative disease with no approved therapies. The new grant program will expand from STATegic’s previous FARA-funded work and will support the further characterization of STATegics’ compounds in preclinical studies.
Jennifer Farmer, MS, CGC, Executive Director at FARA, commented, "We are excited to award a second research grant to STATegics. The data generated from their previous grant is encouraging and this additional funding builds on their excellent progress. FARA recognizes the importance of public-private partnership in getting compounds through discovery and pre-clinical development. FARA is grateful for STATegics' commitment to advancing new therapeutics for Friedreich's ataxia and we look forward to seeing these compounds advance through pre-clinical development to human studies.